The aim of the study was to compare the dose to vaginal points between two intracavitary applicators used for HDR brachytherapy in Carcinoma Cervix
METHODS AND MATERIALS
Patients reporting to our center for Carcinoma cervix intracavitary brachytherapy were randomly allocated to treatment with either Manchester or Fletcher Suit Delclos (FSD) applicator. All patients received an EBRT dose of 50 Gy in 25 fractions along with weekly Cisplatin (40 mg/m2). Brachytherapy was administered using CT based planning. All patients received a dose of 7 Gy to Point A one week apart for a total of three fractions. For vaginal dose reporting, the PIBS points (PIBS, PIBS+1, PIBS+2, PIBS-1, PIBS-2) and dose to vagina at the level of ovoids was compared between the two applicators
A total of 30 Carcinoma cervix patients were randomly allocated to receive intracavitary brachytherapy with either Manchester or FSD applicator. The mean vaginal reference length for patients treated with Manchester applicator was 4.3 and for patients treated with FSD applicator was 4.4. On analyzing dose to different vaginal points, patients treated with Manchester applicator received significantly higher mean and median doses to all PIBS points (except PIBS-2 cm) as compared to FSD applicator. On analyzing dose to the upper vagina at the level of the ovoids, the Manchester applicator delivered higher antero-posterior doses as compared to FSD applicator.
Manchester applicator gives higher dose to the vagina as compared to FSD applicator for intracavitary brachytherapy in Carcinoma Cervix. The choice of using a particular applicator depends on the residual disease at the time of brachytherapy and patient anatomy
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Brachytherapy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Recommendations from gynecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.Radiother Oncol. 2005; 74: 235-245
- Recommendations from gynecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.Radiother Oncol. 2006; 78: 67-77
- Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytheraphy.Radiother Oncol. 2013; 107: 99-105
- Minicolpostats, dome cyclinders, other additions and improvements of the Fletcher-Suit after loading system: indications and limitations of their use.Int. J. Radiat. Oncol. Biol. Phys. 1980; 6: 1195-1206
- After loading technique for radiation therapy of carcinoma of the uterus.Radiology. 1960; 74: 834
- A dosimetric analysis of Morris, Fletcher and Henschke systems for treatment of uterine cervix carcinoma.Int J Radiat Oncol Biol Phys. 1991; 21: 995-1003
- A randomized comparison of two brachytherapy devices for the treatment of uterine cervical carcinoma.Radiother Oncol. 2005; 74: 247-250
- A comparison of dose distribution from Manchester-style and Fletcher-style intracavitary brachytherapy applicator systems in cervical cancer.J Contemp Brachytherapy. 2012; 4: 213-218
- Vaginal dose of radical radiotherapy for cervical cancer in China: a multicenter study.BMC Cancer. 2019; 19: 1219
- Multicenter evaluation of novel vaginal dose reporting method in 153 cervical cancer patients.Radiother Oncol. 2016; 120: 420-442
Published online: October 28, 2021
Accepted: September 18, 2021
Received in revised form: September 7, 2021
Received: May 25, 2021
Disclosures: All authors report no financial and personal relationships with other people or organizations that could bias their work. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
© 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.